BridgeBio is demonstrably improved the progress of a novel therapy for cardiac amyloidosis, utilizing Attruby. Initial clinical information reveals potential benefits for patients diagnosed with a severe condition. This https://attr-cm317128.aioblogs.com/94856290/bridgebio-advances-amyloidosis-management-using-the-drug